Rapid Micro Biosystems (RPID) EBITDA Margin (2020 - 2026)
Rapid Micro Biosystems (RPID) reported EBITDA Margin of 173.11% for Q1 2026, down 1126.0% on a YoY basis from 16.87% in Q1 2025, and down 59.94% sequentially from 108.23% in Q4 2025.
Rapid Micro Biosystems (RPID) EBITDA Margin (2020 - 2026) Analysis & Trends
Rapid Micro Biosystems (RPID) has 7 years of EBITDA Margin data on file, last reported at 173.11% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 1126.0% year-over-year to 173.11%; the trailing twelve-month figure through Mar 2026 stood at 144.2% (up 1537.0% YoY), and the FY2025 full-year result was 141.1%, up 3686.0% from the prior year.
- EBITDA Margin retreated to 173.11% in Q1 2026, from 108.23% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 108.23% in Q4 2025 to a low of 394.6% in Q4 2022.
- A 5-year average of 234.99% and a median of 202.15% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 18742 bps in 2022 and surged 20227 bps in 2023, its largest moves.
- Tracing RPID's EBITDA Margin over 5 years: stood at 394.6% in 2022, then jumped by 51 bps to 192.33% in 2023, then jumped by 35 bps to 124.47% in 2024, then climbed by 13 bps to 108.23% in 2025, then tumbled by 60 bps to 173.11% in 2026.
- Business Quant data shows RPID's EBITDA Margin at 173.11% in Q1 2026, 108.23% in Q4 2025, and 145.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.19 Bn | 173.90 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 128.53 Bn | 125.65 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 107.77 Bn | 98.55 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 67.72 Bn | 66.27 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 48.21 Bn | 44.54 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn | 21.42% |
| 7 | GE HealthCare Technologies | 28.33 Bn | 26.05 Bn | 1.98 Bn | 10.04% |
| 8 | Smith & Nephew | 26.76 Bn | 26.18 Bn | - | - |
| 9 | Koninklijke Philips | 25.27 Bn | 22.15 Bn | 2.07 Bn | 6.17% |
| 10 | Rapid Micro Biosystems | 89.96 Mn | 80.52 Mn | 371,000.00 | -173.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -173.11% |
| Dec 31, 2025 | -108.23% |
| Sep 30, 2025 | -145.09% |
| Jun 30, 2025 | -167.28% |
| Mar 31, 2025 | -161.85% |
| Dec 31, 2024 | -124.47% |
| Sep 30, 2024 | -158.32% |
| Jun 30, 2024 | -202.15% |
| Mar 31, 2024 | -254.38% |
| Dec 31, 2023 | -192.33% |
| Sep 30, 2023 | -235.13% |
| Jun 30, 2023 | -300.96% |
| Mar 31, 2023 | -295.37% |
| Dec 31, 2022 | -394.60% |
| Sep 30, 2022 | -356.32% |
| Jun 30, 2022 | -364.61% |
| Mar 31, 2022 | -360.55% |
| Dec 31, 2021 | -279.49% |
| Sep 30, 2021 | -175.72% |
| Jun 30, 2021 | -177.19% |